Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02504476 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective
A Phase 1 study of Schizophrenia or Schizoaffective Disorder, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 2
- Study locations
NCT02504476 is a Phase 1 study of Schizophrenia or Schizoaffective Disorder that has completed, run by Amgen. The registered enrollment target is 52 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT02504476, a Phase 1 study of Schizophrenia or Schizoaffective Disorder, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to find out the time it takes to absorb, distribute, breakdown and remove the drug from the body in healthy participants and subjects with schizophrenia and whether it causes any side effects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Midazolam
- DRUG AMG 581
Study Locations (2)
California
- Research Site - Glendale
- Parexel - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2015-08 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02504476
The ClinicalTrials.gov registry entry for NCT02504476 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia or Schizoaffective Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02504476 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02504476 about?
NCT02504476 is a clinical study titled "Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective". The purpose of this study is to find out the time it takes to absorb, distribute, breakdown and remove the drug from the body in healthy participants and subjects with schizophrenia and whether it causes any side effects.
What is the current status of trial NCT02504476?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2015-08. Estimated completion is 2016-02.
What conditions does trial NCT02504476 study?
This clinical trial studies the following conditions: Schizophrenia or Schizoaffective Disorder.
What interventions are being tested in trial NCT02504476?
The interventions under investigation include: Placebo (DRUG), Midazolam (DRUG), AMG 581 (DRUG).
Who is sponsoring clinical trial NCT02504476?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02504476 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.